Coming May 2025
Get Early Access
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
11 employees
OncoMyx Therapeutics, a cancer treatment developer, uses a unique virus and patented delivery system to target and treat tumors.
HQ
Founded
2018
OncoMyx Therapeutics, founded in 2018 and headquartered in Phoenix, Arizona, is dedicated to developing innovative cancer treatments. The company's core mission is to harness the power of oncolytic immunotherapies to create effective cancer treatments. Their primary product is a myxoma virus (MYXV) platform designed to target both hematologic and solid tumors. This platform employs a patented systemic delivery method that uses human leukocytes to transport the virus, enabling it to infect and destroy tumor cells. OncoMyx aims to revolutionize cancer treatment by leveraging this unique approach.
The company has garnered attention through its pioneering work and has attracted notable investors and affiliations within the biotech industry. Key achievements include the successful development and initial testing of their MYXV platform, demonstrating its potential efficacy in preclinical models. OncoMyx Therapeutics' innovative approach has positioned it as a promising player in the field of cancer treatment, with the potential to significantly impact patient outcomes and advance the standard of care in oncology.
Operating Status
Active
Ownership Type(s)
Venture Capital, Private
Main Product(s)
Cancer Treatments, Immunotherapies, Cancer Treatment
Technology
Biotech
Tags
Biotech, Healthtech
Model Types
Biotech
Revenue Type(s)
Recurring, Consulting
Customer Type(s)
Enterprise
Geographic Exposure
United States
When was OncoMyx Therapeutics founded?
OncoMyx Therapeutics was founded in 2018.
Where is OncoMyx Therapeutics's headquarters located?
OncoMyx Therapeutics's headquarters is located in Phoenix, AZ, US.
When was OncoMyx Therapeutics's last funding round?
OncoMyx Therapeutics's most recent funding round was for $50M (USD) in December 2021.
How many employees does OncoMyx Therapeutics have?
OncoMyx Therapeutics has 11 employees as of Feb 5, 2024.
How much has OncoMyx Therapeutics raised to-date?
As of July 05, 2023, OncoMyx Therapeutics has raised a total of $50M (USD) since Dec 9, 2021.
Add Comparison
Total Raised to Date
$50M
USD
Last Update Dec 9, 2021
Last Deal Details
$50M
USD
Dec 9, 2021
Series B
Current Employees
11
Last updated: Feb 5, 2024
No location information available for this company.
Locations
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts